Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
This is a Phase 2/3, double-blind, randomized, placebo-controlled, parallel group,
multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and
immunogenicity of ravulizumab in adult participants with dermatomyositis (DM).